Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979716 | 1.00 | HSP90AB1 (0.42) | HSP90AB1MAPTMEN1KMT2AATM | |
| SCHEMBL4976711 | 0.93 | HSP90AB1 (0.41) | HSP90AB1MAPTMEN1KMT2AATM | |
| SCHEMBL4976722 | 0.93 | HSP90AB1 (0.41) | HSP90AB1MAPTMEN1KMT2AATM | |
| SCHEMBL4976337 | 0.90 | HSP90AB1 (0.51) | HSP90AB1MAPTMEN1KMT2ATLR4 | |
| SCHEMBL4978489 | 0.90 | HSP90AB1 (0.51) | HSP90AB1MAPTMEN1KMT2ATLR4 | |
| SCHEMBL4976348 | 0.90 | HSP90AB1 (0.51) | HSP90AB1MAPTMEN1KMT2ATLR4 | |
| SCHEMBL4978474 | 0.90 | HSP90AB1 (0.51) | HSP90AB1MAPTMEN1KMT2ATLR4 | |
| SCHEMBL4976322 | 0.90 | HSP90AB1 (0.43) | HSP90AB1MAPTTLR4TLR9TLR8 | |
| SCHEMBL4976338 | 0.90 | HSP90AB1 (0.43) | HSP90AB1MAPTTLR4TLR9TLR8 | |
| SCHEMBL4974875 | 0.89 | HPGD (0.51) | HSP90AB1MAPTNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | HSP90AB1 2652/4885MAPT 2301/4885MEN1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.